Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative donafenib + tislelizumab for resectable hepatocellular carcinoma
ChiCTR2300073728Phase 2Not yet recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of donafenib and tislelizumab in hepatocellular carcinoma (HCC), sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoints: Recurrence-free survival rate at 12 months and Recurrence-free survival. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
donafenibtislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300073728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073728.